Anastrozole-induced subacute cutaneous lupus erythematosus.
Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) has been associated with numerous drugs, but there are limited reports of its association with aromatase inhibitor anastrozole. We report the case of a patient undergoing treatment with anastrozole for breast cancer who presented with clinical, serological, and histological evidence consistent with DI-SCLE. Her condition quickly began to improve after the use of anastrozole was discontinued and hydroxychloroquine therapy was initiated. Cases such as ours as well as several others that implicate antiestrogen drugs in association with DI-SCLE seem to be contradictory to studies looking at the usefulness of treating systemic lupus erythematosus (SLE) with antiestrogen therapy. Further research on this relationship is warranted.
Department of Dermatology, SUNY Downstate Medical Center, Brooklyn, New York, USA.
Juliya
J
Fisher
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Mital
M
Patel
Department of Dermatology, Metropolitan Hospital Center, New York, New York, USA.
Michael
M
Miller
Northwell Department of Dermatology, Hofstra-Northwell School of Medicine, Hempstead, New York, USA.
Katy
K
Burris
D000368:Aged; D000077384:Anastrozole; D000974:Antibodies, Antinuclear / Q000276:immunology; D001132:Arm; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D009570:Nitriles / Q000009:adverse effects*; D013909:Thorax; D014230:Triazoles / Q000009:adverse effects*
D000974:Antibodies, Antinuclear; D047072:Aromatase Inhibitors; D009570:Nitriles; C035356:SS-A antibodies; D014230:Triazoles; D000077384:Anastrozole